All CD166 / ALCAM reagents are produced in house and quality controlled, including 24 CD166 / ALCAM Antibody, 52 CD166 / ALCAM Gene, 1 CD166 / ALCAM IPKit, 7 CD166 / ALCAM Lysate, 7 CD166 / ALCAM Protein, 3 CD166 / ALCAM qPCR. All CD166 / ALCAM reagents are ready to use.
Recombinant CD166 / ALCAM proteins are expressed by HEK293 Cells with fusion tags as C-His, C-human IgG1-Fc & His, C-human IgG1-Fc.
CD166 / ALCAMantibodies are validated with different applications, which are ELISA, IHC-P, FCM, WB, IP, ICC/IF, IF.
CD166 / ALCAMcDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each CD166 / ALCAM of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.